Back to Blog

Medical Abuse in Claims: Beyond Over-Treatment

Introduction

Within the realms of general liability (GL) and workers’ compensation (WC) insurance lines, medical abuse is often considered in narrow terms — excessive treatment, unnecessary surgeries, inflated bills. While such behaviors are indeed problematic, a wider spectrum of medical abuse exists, deeply impacting claims cost, reserve adequacy, network risk, and insurer liability. This article examines multiple forms of medical abuse in GL and WC claim contexts, maps how they can distort the claims lifecycle, and supports arguments with regulatory and investigative evidence.

Defining Medical Abuse in Claims Contexts

For purposes of this discussion, medical abuse refers to provider or system behaviors in the adjudication, delivery and billing of medical treatment associated with insured injuries that deviate from accepted professional, ethical or business-practices norms. These behaviors may occur without necessarily causing direct physical harm (though they may), but rather distort the claims process and inflate cost. In the GL and WC claim world, medical abuse typically includes:

1. False or inflated billing / services not rendered: Providers billing for examinations, treatments or supplies that were not actually provided or lacked medical justification.
2. Referral or kick-back schemes: Networks of providers, attorneys, clinics or other actors steering claimants into high-cost modalities or prolonged treatment for financial gain.
3. Misleading or boiler-plate provider reports / evaluations: Providers issuing standardized or inappropriate reports (e.g., independent medical exams (IMEs) or assigned medical evaluators (AMEs)) that favor extended treatment, high impairment ratings or liability without proper clinical support.
4. Manipulation of benefit systems or misclassification of injury/illness: Adjusting documentation, diagnoses or classification of workplace exposure to gain broader or more favorable treatment and payment eligibility.
5. Durable medical equipment (DME) and ancillary service abuse: Ordering excessive or unnecessary devices, supplies, transport or ancillary services that drive up claim cost without commensurate clinical value.

Below we explore how each of these manifests, why they matter in the claims context, and how insurers route to detection and mitigation.

False or Inflated Billing / Services Not Rendered

One of the most direct forms of medical abuse is billing for services that were never performed or that lack material justification. Regulatory guidance emphasizes this type of provider misconduct. For example, the California Department of Industrial Relations (DIR) lists as primary behaviors “bill for services never performed” or “misrepresent the nature of the medical services, procedures or supplies” as provider fraud in WC.

In practice within GL and WC claims, this might look like a claimant visiting a provider shortly after a minor accident, being billed for multiple advanced diagnostics and therapies, yet the documentation or chronology does not support the volume of treatment—or the provider submits several claims for overlapping sessions, or bills for new procedures without corresponding progress or medical justification.

From a claims-management standpoint, this is highly significant: costs increase without commensurate value, and it may mask or grease other abuses (e.g., referral schemes, prolonged treatment). Moreover, damages is increased because inflated medical cost may escalate settlement demands.

Referral or Kick-Back Schemes

Another critical vector of medical abuse in GL/WC lines is the referral network or “treating-provider ecosystem” model where providers, attorneys and clinics collaborate (sometimes implicitly) to steer claimants into higher-cost services. For instance, the regulatory commentary on WC fraud identifies providers or attorneys engaging in referral-based billing as a common scheme.

In GL (e.g., auto liability or general liability bodily injury), the analogous phenomenon is when plaintiffs’ counsel refer injured claimants to clinics or pain-management centers known for high-volume injections, durable-medical-equipment (DME) orders, or long-term therapy—even when the documented injury might support a far more modest treatment path. This treatment-escalation not only elevates medical cost but also increases settlement exposure, litigation risk and reserve inflation for carriers.

Misleading or Boiler-plate Provider Reports / Evaluations

Independent medical exams (IMEs), Qualified Medical Evaluators (QMEs – in WC jurisdictions such as California), or other provider-reports, play a pivotal role in determining treatment scope, duration, impairment rating, return-to-work readiness and liability. Abuse occurs when providers issue reports that are cursory, boiler-plate (same language across claimants), or are incongruent with documented clinical interaction. The Nevada Attorney General’s “Provider Fraud” guidance lists as red flags “boilerplate reports” and “extensive treatment especially for minor or subjective injuries.”

In a WC claim, an IME might declare maximal medical improvement (MMI) prematurely, or conversely extend treatment indefinitely by recommending myriad modalities, even when objective improvement is minimal. In GL, a provider’s diagnostic narrative might amplify injury severity to support high settlement demands or extended therapy. For insurers, these mis-reports complicate adjudication, heighten litigation cost, distort reserves and may frustrate subrogation efforts or cost containment strategies.

Manipulation of Classification, Exposure or Documentation

Medical abuse can also manifest in mis‐classification of injuries or manipulation of documentation to exploit benefit systems. For example, in WC, an employer might influence medical reporting so that an employee’s injury appears “work-related” when the facts are weaker, enabling broader treatment coverage or higher indemnity. In GL, the claimant’s provider or attorney may exaggerate causation (e.g., linking unrelated symptoms to an accident) to support more intense treatment.

The New Jersey Workers’ Compensation Fraud Act emphasizes misrepresentation of physical condition, job status or previous trauma for the purpose of wrongfully obtaining benefits. Such manipulations fuel medical cost inflation and challenge claims integrity and underwriting reliability.

Durable Medical Equipment (DME), Ancillary Services & Non‐Clinical Add-ons

Another form of abuse is the over‐ordering of DME, ancillary services (transportation, home care, extended therapy) that may be marginal in clinical value but high in cost. The DIR’s fraud-prevention material lists “inappropriate treatment” or “improper codes” by medical providers among typical fraudulent patterns in WC.

In GL or WC claims, a minor soft-tissue injury might result in months of home-health services, repeated private-therapy sessions, transport to/from clinic, and large bills for equipment, far beyond what standards of care would dictate. While each service may seem plausible in isolation, aggregated they produce outsized cost and may indicate a network orientated to maximizing reimbursement rather than supporting efficient recovery.

Why Medical Abuse Matters for GL and WC Claimants and Insurers

Cost and Severity Escalation

Medical abuse directly drives up medical cost per claim. In WC and GL lines, medical treatment often constitutes a substantial share of claim expense. When providers exploit the system (excessive treatment, inflated bills, referral networks), each claim’s potential settlement increases. Over‐treatment accelerates cost, but the other forms of abuse described (billing for services not rendered, referral kick-backs, DME over-ordering, manipulating classification) also raise the baseline. This cost escalation strains reserves, elevates stop-loss exposure, and increases indemnity cost (especially in WC when treatment prolongs disability).

Duration and Tail Risk

Claims afflicted by medical abuse often last longer. For example, a claimant who is steered into extended therapy or multiple procedures may remain under treatment for months or years, delaying closure. In WC, this extended treatment delays return to work, increases indemnity, and creates a larger case-management burden. For GL, extended treatment may mean higher settlement exposure, longer litigated file life, and less predictability. Tail risk becomes heightened; the carrier must reserve not only more dollars but potentially for a longer payment horizon.

Reserve and Actuarial Distortion

Accurate reserving and actuarial modelling depends on stable, predictable utilization patterns. When medical abuse skews treatment volume, coding patterns and service pricing, loss triangles shift unfavorably. This distortion challenges underwriting, premium calculations and profitability forecasting. For example, when provider networks in a region exhibit high rates of “medical mills” (referral networks delivering high-volume treatment regardless of clinical necessity), historical cost baselines may under‐state future cost risk.

Litigation, Subrogation and Network Risk

Inflated medical cost or questionable provider networks also increase litigation and subrogation complexity. When treatment is excessive or questionable, defense counsel may challenge causation or necessity, amplifying legal cost and liability. From a subrogation perspective (particularly in GL claims with third-party liability exposures), inflated medical cost can complicate recovery because of potential lien issues, provider referral networks or fraud-associated attribution. Additionally, network risk arises: if a carrier allows or contracts with providers with unethical patterns, reputational, regulatory and financial risk escalate.

Regulatory and Compliance Consequences

Providers who engage in fraudulent billing, referral kick-backs or mis-reporting face regulatory suspension, liability and exclusion. For example, the California DIR suspended 178 medical providers in the first eight months of 2022 for fraud-related reasons. When a provider network contains such high-risk providers, the carrier’s exposure increases. Insurers must manage compliance risk, potential recoupments and network disruption. Furthermore, neglected detection of medical abuse may lead to regulatory scrutiny of the carrier or plan.

Detection, Red Flags and Claims Workflow Integration

To manage the risk of medical abuse, GL and WC claims professionals must integrate detection strategies early and continuously. Key red flags include:

• Providers with unusually high average cost per claim or treatment volume relative to peer group benchmarks.
• Clinics or physicians with referral patterns inconsistent with typical injury causation (e.g., high injection volume for minor soft-tissue injuries).
• Billing for services on weekends/holidays or with overlapping time entries. Nevada’s provider-fraud guidance flags “weekend/holiday billings” and duplicated billing.
• Reports (IME/QME) that are boiler-plate in language across claimants or that deviate markedly from examining physician notes.
• Treatment plans that persist beyond expected recovery timelines without meaningful improvement or return to work.
• Durable medical equipment or ancillary service orders that appear disproportionate to the injury or follow-up.
• Claimants rapidly funneled to specific clinics or providers by attorneys or “steerer” networks.
• Provider has financial interest in referral services (e.g., ownership of therapy clinic, imaging center) or the claimant is sent to network providers repeatedly without objective change.
• Patterns of misclassification of injury or employer/claimant statements inconsistent with medical/imaging findings.
• State regulatory action or provider exclusion lists published (e.g., suspended providers in California).

When such indicators surface, the claims workflow should trigger: utilization review, provider credentialing check, audit of billing and clinical documentation, early intervention (e.g., case-management referral), and potential network exclusion.

Strategic Response for Insurers, Employers and Claims Managers

Establish Analytics and Provider-Profiling

Carriers should invest in claims data analytics that profile provider behavior over time, tracking cost per claim, modality utilization, treatment duration and outcome (return to work, closure time). Unsupervised machine-learning research has shown promise in healthcare fraud detection by identifying providers with outlier billing patterns. Building such profiles helps insurers identify high-risk networks in GL/WC portfolios.

Medical-Cost Management and Functional Recovery Focus

Claims managers must shift focus from simply paying bills to managing outcomes: verifying that each treatment is justified, monitoring progress, challenging repeated referrals to high-cost modalities without improvement, and encouraging early return-to-work (especially in WC contexts). Utilization review, concurrent review and case-management integration are critical.

Provider Credentialing and Network Design

Insurers and self-insured employers should implement rigorous credentialing: verifying providers past billing patterns, referrals, sanction history, ownership of ancillary services, and network reputational standing. Contracts should include termination clauses for providers who demonstrate abusive patterns. Preferred provider networks (PPNs) should be structured around outcome metrics, not just volume. In GL settings, adjusters should monitor for referral loops to high-cost clinics.

Audit, Recovery and Subrogation Strategies

Retrospective audits of high-cost claims are essential. When over‐billing or referral kick-back schemes are suspected, recoveries may be pursued, and providers may be excluded. In WC, regulators (e.g., California DIR) publish lists of suspended providers; insurers must integrate this information.

Product and Underwriting Implications

Underwriting models in GL and WC must incorporate “treatment-inflation risk” or “provider-network abuse risk” into loss cost assumptions. Self-insured employers should review provider networks prior to adoption and monitor ongoing usage. Products may include cost-containment features such as pre-authorization for high-cost services, second-opinion requirements, or managed-care networks with measured outcomes.

Challenges and Considerations

• Balancing Access to Care and Oversight: Claims professionals must ensure injured parties receive appropriate care while still safeguarding against abuse. Over-restriction may result in under-treatment, which itself can lead to worse outcomes and liability.
• Clinical Judgment vs. Abuse Boundary: Distinguishing legitimate complex treatment from abusive escalation requires clinical review and expert input. Poor documentation or ambiguous injury patterns complicate this.
• Data Limitations and Provider Behavior Transparency: Claims data alone may not capture the full clinical picture. Setting up provider-behavior metrics requires investment, and providers may adapt behavior (e.g., shifting treatment codes) in response to scrutiny.
• Extended Tail Risk: Abuse may remain hidden until late in the claim lifecycle (e.g., when settlement is approached or when provider networks are legally challenged). Reserving for long-tail risk is therefore critical.
• Legal and Regulatory Variation Across Jurisdictions: WC and GL systems vary by state; provider fraud statutes, reporting requirements, and sanctions differ. Insurers operating multi‐state portfolios must navigate this complexity.
• Provider Network Disruption: Excluding providers for abusive patterns may disrupt claimant access or network availability, especially in rural/geographically limited markets.

Conclusion

Medical abuse in GL and WC claims is multifaceted extending far beyond the familiar marker of “too much treatment.” False billing, referral kickbacks, deficient provider reports, classification manipulation and oversized ancillary costs all distort the cost, duration and outcome of claims. For insurers, self-insured employers and claims managers, these abuses translate into elevated cost, longer tail exposures, distorted reserves, litigation amplification and network risk.

To mitigate these outcomes, a robust framework is necessary: analytics-driven provider profiling, early utilization review, functional-outcome monitoring, rigorous credentialing, audit practices, compliance engagement and underwriting recognition of provider-network risk. Given regulatory momentum (e.g., the California DIR suspensions of hundreds of providers for fraud-related conduct) and evolving treatment modalities, the risk landscape is only becoming more complex. In this context, claim professionals who proactively identify and manage medical-abuse exposure will strengthen control over cost, duration and claim quality—and better protect insurers, employers and injured parties alike.